Pirfenidone (Esbriet) prior authorization at Geisinger Health Plan
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Geisinger Health Plan requires prior-authorization documentation for Pirfenidone (Esbriet): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Geisinger Health Plan reviews Pirfenidone (Esbriet) prior authorizations against its medical policy . Geisinger Health Plan-specific context: Integrated payer-provider system in central/northeast Pennsylvania (~600K members). Acquired by Kaiser-affiliated Risant Health in March 2024 — operational integration ongoing. PA Insurance Department oversight. Strong MA presence in service area.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Geisinger Health Plan's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Narrow-network denials outside Geisinger system
- Specialty referral coordination
- Medicare Advantage step therapy on Part B drugs
- Out-of-network non-emergency
Pirfenidone (Esbriet)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- FVC threshold requirements (plan demands 50-80% predicted)
- Step therapy requiring nintedanib first
- Liver function monitoring not documented
- Confirmation of IPF diagnosis by HRCT + multidisciplinary review
Brand: Esbriet. Antifibrotic for IPF. Multiple generics available since 2022. Photosensitivity warning. CAPACITY and ASCEND trial program.
Manufacturer patient-assistance program: Genentech Access Solutions — relevant when a Geisinger Health Plan denial sticks and the patient needs bridge access while appealing.
How Geisinger Health Plan approaches Antifibrotic agents PAs
For Pirfenidone, check whether the current Geisinger Health Plan Antifibrotic agents policy cites specialty referral coordination or medicare advantage step therapy on part b drugs. Pharmacy-benefit review for Pirfenidone at Geisinger Health Plan is routed through Geisinger Pharmacy (in-house, integrated payer-provider). The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Geisinger Health Plan; if denied, use the filing date and route printed on that denial notice. Geisinger Health Plan's FVC-threshold restrictions are increasingly out of step with ATS/ERS/JRS/ALAT 2022 guidance, which recommends antifibrotic initiation regardless of FVC band. Geisinger Health Plan is domiciled in PA, so unresolved appeals escalate to the PA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.geisinger.org/health-plan/providers) with the same packet plus an applicable, current clinical source supporting Pirfenidone (Esbriet)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Geisinger Health Plan denial on DenialHelp.
Contact Geisinger Health Plan
- Provider portal: https://www.geisinger.org/health-plan/providers
Frequently asked questions
What documentation does Geisinger Health Plan need for Pirfenidone (Esbriet) prior auth?
Geisinger Health Plan's typical PA packet for Pirfenidone (Esbriet): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Geisinger Health Plan?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for Pirfenidone (Esbriet) at Geisinger Health Plan?
Preparation scenarios to check against the current notice and policy include: Narrow-network denials outside Geisinger system; Specialty referral coordination; Medicare Advantage step therapy on Part B drugs. These are not measured frequency claims. For Pirfenidone (Esbriet), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
Does Geisinger Health Plan's FVC threshold for Pirfenidone match current ATS guidance?
Compare the current Geisinger Health Plan antifibrotic policy with the current ATS/ERS/JRS/ALAT IPF guidance and the member's clinical record. If relevant, attach the HRCT report, multidisciplinary discussion, and specific FVC value with rate of decline; the treating clinician must verify the applicability of every source. Pharmacy-benefit handling is routed through Geisinger Pharmacy (in-house, integrated payer-provider). External-review escalation for Geisinger Health Plan fully-insured policies sits with the PA insurance department.
How do I prep for a peer-to-peer with Geisinger Health Plan on Pirfenidone (Esbriet)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Pirfenidone (Esbriet) PA packet
Open ApprovalHelp — generate a Pirfenidone (Esbriet) prior-auth packet tailored to Geisinger Health Plan's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com